4-氯-3-氟苯腈 | 110888-15-8

• 物质功能分类: 有机原料 - 有机氟化合物 - 氟苯腈系列
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氯-3-氟苯腈
• 中文别名: 4-氯-3-氟苯甲腈；3-氟-4-氯苯腈
• 英文名称: 4-chloro-3-fluorobenzonitrile
• 英文别名: 3-fluoro-4-chlorobenzonitrile
• CAS: 110888-15-8
• 化学式: C₇H₃ClFN
• mdl: MFCD00143291
• 分子量: 155.559
• InChiKey: GWZQVECNESCSKR-UHFFFAOYSA-N

物化性质

• 熔点：
  79-81°C
• 沸点：
  214.0±20.0 °C(Predicted)
• 密度：
  1.33±0.1 g/cm3(Predicted)
• 溶解度：
  溶于甲醇
• 稳定性/保质期：
  常温常压下稳定，避免与强氧化剂接触。

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  23.8
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险等级：
  6.1
• 危险品标志：
  Xi,T
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R20/21/22
• 危险品运输编号：
  3439
• 海关编码：
  2926909090
• 包装等级：
  III
• 危险类别：
  6.1
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  密封储存于阴凉干燥的库房，并远离氧化剂。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
4-Chloro-3-fluorobenzonitrile
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H311: Toxic in contact with skin
H302: Harmful if swallowed
H332: Harmful if inhaled
H315: Causes skin irritation
Causes serious eye irritation
H319:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P309: IF exposed or you feel unwell:
P310: Immediately call a POISON CENTER or doctor/physician

---

Section 3. Composition/information on ingredients.
4-Chloro-3-fluorobenzonitrile
Ingredient name:
CAS number: 110888-15-8

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C7H3ClFN
Molecular weight: 155.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
UN Number: UN3439 Class: 6.1 Packing group: III
Proper shipping name: NITRILES, TOXIC, SOLID, N.O.S. (4-Chloro-3-fluorobenzonitrile)

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

化学性质：本品为固体，在水中不溶，可溶于苯和甲苯。

用途：4-氯-3-氟-苯腈是除草剂氰氟草酯（Cyhalofop-butyl，商品名稗净）的中间体。

生产方法：其制备方法是以3,4-二氯苯腈与氟化钾反应获得。

反应信息

• 作为反应物：
  描述：

  4-氯-3-氟苯腈 在 盐酸 、 sodium methylate 作用下， 以 甲醇 、 乙醇 、 氯仿 为溶剂， 生成 2-(4-chloro-3-fluorophenyl)-6-methylpyrimidin-4-one
  参考文献：
  名称：

  发现和生物学评价新型的4-氨基-2-苯基嘧啶衍生物作为有效和口服活性的GPR119激动剂

  摘要：

  合成了新型的4-氨基-2-苯基嘧啶衍生物，并将其评估为GPR119激动剂。优化2-位苯环上的取代基和4-位氨基上的取代基，可以鉴定出显示出强效GPR119激动活性的3,4-二卤代和2,4,5-三卤代苯基衍生物。发现高级类似物（2 R）-3-{[2-（4-氯-2,5-二氟苯基）-6-乙基嘧啶-4-基]氨基}丙烷-1,2-二醇（24g）可以改善在小鼠中口服1 mg / kg的葡萄糖耐量，并在小鼠和猴子中表现出出色的药代动力学特征。在单日治疗一周后，化合物24g在糖尿病kk / Ay小鼠中也显示出优异的抗糖尿病作用。这些结果表明，新型GPR119激动剂24g 不仅可以通过增强葡萄糖依赖性胰岛素的分泌来改善葡萄糖耐受性，还可以通过保留胰腺β细胞功能来改善葡萄糖耐受性。

  DOI：

  10.1016/j.bmc.2012.06.049
• 作为产物：
  描述：

  4-氯-3-氟苯甲酸 在 氯化亚砜 、 氨 、 三氯氧磷 作用下， 以 N,N-二甲基甲酰胺 、 氯仿 、 水 为溶剂， 反应 6.5h， 以92.4%的产率得到4-氯-3-氟苯腈
  参考文献：
  名称：

  一种工业化制备2,3-二氟三氟甲苯、3,4-二氟 苯腈的连续生产方法

  摘要：

  本发明公开一种工业化制备2,3‑二氟三氟甲苯、3,4‑二氟苯腈的连续生产方法，其中2,3‑二氟三氟甲苯涉及苯磺酰胺和苯磺酰脲类除草剂的中间体原料的制备方法，3,4‑二氟苯腈涉及氰氟草脂中间体原料的制备方法，该方法适用于工业化生产，相对于现有方法成本低，生产效率高，污染少。

  公开号：

  CN107488098B

文献信息

• [EN] PYRIMIDINE, PYRIDINE AND TRIAZINE DERIVATIVES AS MAXI-K CHANNEL OPENERS.<br/>[FR] DÉRIVÉS DE PYRIMIDINE, PYRIDINE ET TRIAZINE EN TANT QU'OUVREURS DE CANAUX MAXI-K
  申请人：MITSUBISHI TANABE PHARMA CORP

  公开号：WO2009125870A1

  公开（公告）日：2009-10-15

  A compound of formula (A); wherein ring A is an aromatic ring or a heteroaromatic ring; R1 is independently halogen, cyano, etc., each of X1, X2 and X3 is CR2 or nitrogen, R2 is independently hydrogen, etc., n is 0, 1, 2, 3 or 4; -D-Y is -O-CH2COOH, etc, and G is a substituted amino, a substituted heterocyclic group, etc, or a pharmaceutical acceptable salt thereof, has activities of opening BK channels.

  化合物的结构式（A）；其中环A是芳香环或杂芳环；R1独立地是卤素、氰基等；X1、X2和X3中的每一个是CR2或氮，R2独立地是氢等；n为0、1、2、3或4；-D-Y是-O-CH2COOH等；G是取代氨基、取代杂环基等，或其药用可接受盐，具有开放BK通道的活性。
• [EN] COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS<br/>[FR] COMPOSÉS ET LEUR UTILISATION EN TANT QU'ACTIVATEURS DE PDE4
  申请人：MIRONID LTD

  公开号：WO2018060704A1

  公开（公告）日：2018-04-05

  Compounds of Formula (I), which are activators of long form cyclic nucleotide phosphodiesterase-4 (PDE4) enzymes (isoforms) are provided. Methods and uses of these compounds for the treatment or prevention of disorders requiring a reduction of second messenger responses mediated by cyclic 3', 5'-adenosine monophosphate (cAMP) are also described. (Formula (I))

  Formula (I)的化合物是长形环核苷酸磷酸二酯酶-4（PDE4）酶（同工酶）的激活剂。还描述了这些化合物用于治疗或预防需要通过环3'，5'-腺苷酸单磷酸（cAMP）介导的第二信使反应减少的疾病的方法和用途。
• Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
  申请人：Link T. James

  公开号：US20050277647A1

  公开（公告）日：2005-12-15

  The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions that are mediated by excessive glucocorticoid action.

  本发明涉及抑制11-β-羟基类固醇脱氢酶1型酶的化合物。本发明还涉及利用11-β-羟基类固醇脱氢酶1型酶的抑制剂治疗非胰岛素依赖型2型糖尿病、胰岛素抵抗、肥胖、脂质紊乱、代谢综合征以及其他由过度糖皮质激素作用介导的疾病和症状。
• [EN] KCNT1 INHIBITORS AND METHODS OF USE<br/>[FR] INHIBITEURS DE KCNT1 ET PROCÉDÉS D'UTILISATION
  申请人：PRAXIS PREC MEDICINES INC

  公开号：WO2020227101A1

  公开（公告）日：2020-11-12

  The present invention is directed to, in part, compounds and compositions useful for preventing and/or treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene (e.g., KCNT1). Methods of treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene such as KCNT1 are also provided herein.

  本发明部分涉及用于预防和/或治疗神经系统疾病或紊乱、与过度神经元兴奋性有关的疾病或病况，以及基因（例如KCNT1）中的功能增强突变的化合物和组合物。本文还提供了治疗神经系统疾病或紊乱、与过度神经元兴奋性有关的疾病或病况，以及基因如KCNT1中的功能增强突变的方法。
• [EN] SUBSTITUTED PYRROLO TRIAZINE CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN EP3 RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS DE PYRROLO TRIAZINE CARBOXAMIDE SUBSTITUÉS EN TANT QU'ANTAGONISTES DU RÉCEPTEUR DE LA PROSTAGLANDINE EP3
  申请人：BAYER AG

  公开号：WO2021094209A1

  公开（公告）日：2021-05-20

  The invention relates to substituted pyrrole triazine carboxamide derivatives of formula (I) and to processes for their preparation, and also /to their use for preparing medicaments for the treatment and/ or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and diabetes, and also urogenital and ophthalmic disorders.

  这项发明涉及式(I)的取代吡咯三嗪羧酰胺衍生物，以及它们的制备方法，还有用于制备治疗和/或预防疾病的药物，特别是心血管疾病，优选为血栓性或血栓栓塞性疾病，糖尿病，以及泌尿生殖和眼科疾病。